Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Advanced systemic mastocytosis
Chemotherapy
Cladribine
Purine analogue
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
07
11
2022
accepted:
13
03
2023
medline:
17
7
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
We sought to evaluate the efficacy of the purine analogue cladribine in 79 patients with advanced systemic mastocytosis (AdvSM) using data from the 'German Registry on Disorders of Eosinophils and Mast Cells (GREM)'. The overall response rate according to modified Valent criteria (46 evaluable patients) for first- (1L) and second-line (2L) cladribine treatment was 41% (12/29) and 35% (6/17, P = 0.690), respectively, and the median overall survival (OS, all patients evaluable) was 1.9 years (n = 48) and 1.2 years (n = 31; P = 0.311). Univariate and multivariable analyses of baseline and on-treatment parameters identified diagnosis of mast cell leukemia (hazard ratio [HR] 3.5, 95% confidence interval [CI, 1.3-9.1], P = 0.012), eosinophilia ≥ 1.5 × 10
Identifiants
pubmed: 37012462
doi: 10.1007/s00277-023-05180-y
pii: 10.1007/s00277-023-05180-y
pmc: PMC10344834
doi:
Substances chimiques
Cladribine
47M74X9YT5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2077-2085Subventions
Organisme : José Carreras Leukämie-Stiftung
ID : DJCLS 08R/2020
Organisme : Austrian Science Fund
ID : SFB F4704-B20
Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2016 Jun 30;374(26):2605-7
pubmed: 27355555
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
Blood. 2015 Aug 20;126(8):1009-16; quiz 1050
pubmed: 26002962
Leukemia. 2015 May;29(5):1115-22
pubmed: 25567135
Eur J Clin Invest. 2007 Jun;37(6):435-53
pubmed: 17537151
Am J Hematol. 2021 Apr 1;96(4):508-525
pubmed: 33524167
Oncotarget. 2015 Jul 30;6(21):18250-64
pubmed: 26158763
Leukemia. 2022 Aug;36(8):2108-2120
pubmed: 35790816
Lancet Haematol. 2019 Dec;6(12):e638-e649
pubmed: 31676322
Leukemia. 2016 Dec;30(12):2342-2350
pubmed: 27416984
Ann Hematol. 2014 Jan;93(1):81-8
pubmed: 24281161
Leuk Res. 2003 Jul;27(7):635-41
pubmed: 12681363
Blood Adv. 2018 Nov 13;2(21):2964-2972
pubmed: 30413432
Leukemia. 2019 May;33(5):1124-1134
pubmed: 30635631
Leukemia. 2018 Feb;32(2):470-478
pubmed: 28744009
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Eur J Clin Invest. 2016 May;46(5):392-7
pubmed: 26914980
J Clin Oncol. 2019 Nov 1;37(31):2846-2856
pubmed: 31509472
Nat Med. 2021 Dec;27(12):2192-2199
pubmed: 34873345
Leukemia. 2020 Apr;34(4):1090-1101
pubmed: 31740811
Future Oncol. 2022 Apr;18(13):1583-1594
pubmed: 35114819
Blood. 2003 Dec 15;102(13):4270-6
pubmed: 12933573
Nat Med. 2021 Dec;27(12):2183-2191
pubmed: 34873347
Leukemia. 2016 Jan;30(1):136-43
pubmed: 26464169
J Clin Oncol. 2022 Jun 1;40(16):1783-1794
pubmed: 35235417
N Engl J Med. 2016 Jun 30;374(26):2530-41
pubmed: 27355533
Leukemia. 2019 May;33(5):1195-1205
pubmed: 30911112
Blood. 2017 Jul 13;130(2):137-145
pubmed: 28424161
Br J Haematol. 2022 Feb;196(4):975-983
pubmed: 34729775
Blood. 2013 Oct 3;122(14):2460-6
pubmed: 23958953
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
Lancet Haematol. 2021 Mar;8(3):e194-e204
pubmed: 33508247
Br J Haematol. 2003 Sep;122(5):695-717
pubmed: 12930381
Blood. 2020 Apr 16;135(16):1365-1376
pubmed: 32106312
Blood Adv. 2022 Nov 8;6(21):5750-5762
pubmed: 35640224
Am J Hematol. 2009 Dec;84(12):790-4
pubmed: 19890907
Haematologica. 2017 Jun;102(6):1035-1043
pubmed: 28255023
Int J Mol Sci. 2021 Mar 04;22(5):
pubmed: 33806359